Training Program in Investigative Gastroenterology and Hepatology

胃肠病学和肝病学研究培训计划

基本信息

项目摘要

The burden of digestive diseases in the United States is staggering, with annual costs exceeding $140 billion, based on National Institutes of Health (NIH) estimates. To meet this challenge, a key mission of the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) is to support the training of a talented, diverse pool of young investigators who will attack scientific unmet needs to improve the lives of patients with gastrointestinal and liver diseases. The Icahn School of Medicine at Mount Sinai (ISMMS) has been a center of excellence for care in gastrointestinal and liver diseases for decades, with clinical fellowship programs in these disciplines consistently ranked among the best in the country. Moreover, ISMMS offers a fertile environment from which a cadre of outstanding candidates have launched successful careers in academic gastroenterology and hepatology. The overarching goal of this Training Program proposal is to leverage this outstanding environment to support the training of M.D., M.D./Ph.D or Ph.D. postdoctoral fellows by providing exceptional research opportunities and mentorship in three broad areas: A) Gastrointestinal inflammation and the microbiome; B) Non-alcoholic steatohepatitis (NASH), hepatic inflammation and fibrosis; and C) Genetics of gastrointestinal and liver diseases. The highly structured training program provides a tailored curriculum that integrates clinico-epidemiologic-, genetic-, environmental- and cellular/molecular research excellence. The program is built upon a foundation of world class research faculty who have outstanding track records of academic achievement and successful mentorship. The curriculum focuses on cross-disciplinary training in order to prepare trainees for the current and future challenges of gastrointestinal and liver disease research, which now requires integration of complementary research skill sets. To address this need, a highly selected pool of mentors has been chosen not only from within the Divisions of GI and Liver Diseases and other clinical disciplines, but who also represent outstanding multi-disciplinary institutes at the ISMMS. Each year this program will support 3 trainees (PGY 4 - PGY 6), with 15 candidates entering the program over 5 years. Each trainee will pursue an individualized research project and tailored curriculum formulated together with their primary and secondary mentors, curriculum committee and the Program Directors. Trainees will dedicate at least 90% effort in either the laboratory or clinical setting, and their progress will be monitored through quarterly meetings with their advisory committee and program directors. Overall quality and adaptability of the program will be ensured through oversight by internal and external advisory boards, based on compliance with defined metrics of success for both individual trainees and the overall program. This rigorously structured and closely monitored program, committed to excellence and built upon a rich scientific environment and outstanding faculty, will yield superbly trained future leaders in investigative gastroenterology and hepatology.
美国消化系统疾病的负担是惊人的,每年的成本超过1400亿美元,

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SCOTT L. FRIEDMAN其他文献

SCOTT L. FRIEDMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SCOTT L. FRIEDMAN', 18)}}的其他基金

Hepatic stellate cells in NASH fibrosis and HCC
NASH 纤维化和 HCC 中的肝星状细胞
  • 批准号:
    10350710
  • 财政年份:
    2021
  • 资助金额:
    $ 26.83万
  • 项目类别:
Hepatic stellate cells in NASH fibrosis and HCC
NASH 纤维化和 HCC 中的肝星状细胞
  • 批准号:
    10182514
  • 财政年份:
    2021
  • 资助金额:
    $ 26.83万
  • 项目类别:
Hepatic stellate cells in NASH fibrosis and HCC
NASH 纤维化和 HCC 中的肝星状细胞
  • 批准号:
    10597033
  • 财政年份:
    2021
  • 资助金额:
    $ 26.83万
  • 项目类别:
Therapeutic antibodies for treating liver fibrosis
用于治疗肝纤维化的治疗性抗体
  • 批准号:
    10666671
  • 财政年份:
    2020
  • 资助金额:
    $ 26.83万
  • 项目类别:
Therapeutic antibodies for treating liver fibrosis
用于治疗肝纤维化的治疗性抗体
  • 批准号:
    10547688
  • 财政年份:
    2020
  • 资助金额:
    $ 26.83万
  • 项目类别:
Therapeutic antibodies for treating liver fibrosis
用于治疗肝纤维化的治疗性抗体
  • 批准号:
    10011650
  • 财政年份:
    2020
  • 资助金额:
    $ 26.83万
  • 项目类别:
Liver Cancer (LC) (Project-003)
肝癌 (LC)(项目-003)
  • 批准号:
    8932193
  • 财政年份:
    2015
  • 资助金额:
    $ 26.83万
  • 项目类别:
Autophagy during hepatic stellate cell activation in alcoholic liver injury
酒精性肝损伤肝星状细胞激活过程中的自噬
  • 批准号:
    8334729
  • 财政年份:
    2011
  • 资助金额:
    $ 26.83万
  • 项目类别:
Autophagy during hepatic stellate cell activation in alcoholic liver injury
酒精性肝损伤肝星状细胞激活过程中的自噬
  • 批准号:
    8504895
  • 财政年份:
    2011
  • 资助金额:
    $ 26.83万
  • 项目类别:
Autophagy during hepatic stellate cell activation in alcoholic liver injury
酒精性肝损伤肝星状细胞激活过程中的自噬
  • 批准号:
    8705327
  • 财政年份:
    2011
  • 资助金额:
    $ 26.83万
  • 项目类别:

相似海外基金

Integrating Treatments for Alcohol Use Disorder into Hepatology Clinics
将酒精使用障碍的治疗纳入肝病诊所
  • 批准号:
    10785211
  • 财政年份:
    2023
  • 资助金额:
    $ 26.83万
  • 项目类别:
Testing an mHealth System for Integrating Alcohol Use Treatment with Hepatology Care for Patients with Alcohol-associated Liver Disease
测试将酒精使用治疗与肝病护理相结合的移动医疗系统,以治疗酒精相关性肝病患者
  • 批准号:
    10818885
  • 财政年份:
    2023
  • 资助金额:
    $ 26.83万
  • 项目类别:
Translational Research Training in Hepatology
肝病学转化研究培训
  • 批准号:
    10411845
  • 财政年份:
    2022
  • 资助金额:
    $ 26.83万
  • 项目类别:
Translational Research Training in Hepatology
肝病学转化研究培训
  • 批准号:
    10620808
  • 财政年份:
    2022
  • 资助金额:
    $ 26.83万
  • 项目类别:
HEP DART 2021: FRONTIERS IN DRUG DEVELOPMENT FOR HEPATOLOGY
HEP DART 2021:肝病药物开发前沿
  • 批准号:
    10391910
  • 财政年份:
    2021
  • 资助金额:
    $ 26.83万
  • 项目类别:
Multidisciplinary Research Training in Gastroenterology and Hepatology
胃肠病学和肝病学多学科研究培训
  • 批准号:
    9922266
  • 财政年份:
    2019
  • 资助金额:
    $ 26.83万
  • 项目类别:
Multidisciplinary Research Training in Gastroenterology and Hepatology
胃肠病学和肝病学多学科研究培训
  • 批准号:
    10400886
  • 财政年份:
    2019
  • 资助金额:
    $ 26.83万
  • 项目类别:
Multidisciplinary Research Training in Gastroenterology and Hepatology
胃肠病学和肝病学多学科研究培训
  • 批准号:
    10612780
  • 财政年份:
    2019
  • 资助金额:
    $ 26.83万
  • 项目类别:
HEP DART 2019: Frontiers in Drug Development for Hepatology
HEP DART 2019:肝病药物开发前沿
  • 批准号:
    9914390
  • 财政年份:
    2019
  • 资助金额:
    $ 26.83万
  • 项目类别:
Multidisciplinary Research Training in Gastroenterology and Hepatology
胃肠病学和肝病学多学科研究培训
  • 批准号:
    10632345
  • 财政年份:
    2019
  • 资助金额:
    $ 26.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了